Dyadic International (DYAI) Other Working Capital Changes (2018 - 2026)
Dyadic International's (DYAI) quarterly Other Working Capital Changes came in at -$44908.0 in Q1 2026, up 51.29% year-over-year from -$29682.6 in Q1 2025, and up 62.85% quarter-over-quarter from -$120880.0 in Q4 2025.
Analysis
Dyadic International (DYAI) Other Working Capital Changes (2018 - 2026) Analysis & Trends
Dyadic International has disclosed Other Working Capital Changes across 9 years of filings, most recently posting -$44908.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 51.29% year-over-year to -$44908.0; the TTM figure through Mar 2026 stood at -$36670.0 (down 17.21% YoY), while the FY2025 annual figure was -$83964.0, down 239.36% from the prior year.
- Other Working Capital Changes came in at -$44908.0 for Q1 2026 at Dyadic International, up from -$120880.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $1.2 million in Q2 2025 to a low of -$620282.0 in Q1 2026.
- Average Other Working Capital Changes over 5 years is $56436.6, with a median of $24464.0 recorded in 2023.
- The largest YoY upside for Other Working Capital Changes was 104.3% in 2023 against a maximum downside of 907.5% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$44117.0 in 2022, then tumbled by 907.5% to -$444479.0 in 2023, then soared by 84.0% to -$71128.0 in 2024, then tumbled by 69.95% to -$120880.0 in 2025, then soared by 62.85% to -$44908.0 in 2026.
- Per Business Quant data, the three most recent Other Working Capital Changes figures were -$44908.0 in Q1 2026, -$120880.0 in Q4 2025, and $254966.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.38 Bn | 192.39 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.22 Bn | 177.04 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.42 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.97 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.49 Bn | 55.30 Bn | 1.37 Bn |
| 6 | Moderna | 53.90 Bn | 48.76 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.11 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -620,282.00 |
| Mar 31, 2026 | -620,282.00 |
| Dec 31, 2025 | 393,714.00 |
| Dec 31, 2025 | 393,714.00 |
| Sep 30, 2025 | -496,393.00 |
| Sep 30, 2025 | -496,393.00 |
| Jun 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | -168,597.00 |
| Mar 31, 2025 | -168,597.00 |
| Dec 31, 2024 | 319,330.00 |
| Dec 31, 2024 | 319,330.00 |
| Sep 30, 2024 | 32,160.00 |
| Sep 30, 2024 | 32,160.00 |
| Jun 30, 2024 | -51,695.00 |
| Jun 30, 2024 | -51,695.00 |
| Mar 31, 2024 | 43,905.00 |
| Mar 31, 2024 | 43,905.00 |
| Dec 31, 2023 | 581,723.00 |
| Dec 31, 2023 | 581,723.00 |